IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (NASDAQ:ELGX), the developer and manufacturer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that the one-year results from its Powerlink XL® prospective, multi-center clinical trial will be presented on November 20, 2008 at the 35th Annual VEITH Symposium™ being held in New York City. Data from this clinical study were obtained under a U.S. Food and Drug Administration-approved Investigational Device Exemption (IDE) and were submitted to the Agency earlier this year.
